Created with Sketch.
The ASCO Post Podcast
15 minutes | a month ago
News From the 2020 San Antonio Breast Cancer Symposium
The San Antonio Breast Cancer Symposium took place virtually from December 8 to 12th. This week, we’re featuring three important studies from the meeting, focusing on a new prognostic tool; the treatment of depression and related symptoms in young breast cancer survivors; and a chemoimmunotherapy regimen for triple-negative disease.To listen to more podcasts from ASCO, visit asco.org/podcasts.
13 minutes | a month ago
More News From ASH: Whole-Genome Sequencing of Myeloproliferative Neoplasms and More
This week, we’ll focus further on studies presented at the 2020 ASH Annual Meeting & Exposition, including findings on the use of whole-genome sequencing to trace the origins of a blood cancer; stem cell transplant for older patients with myelodysplastic syndromes; and a triplet therapy for relapsed and refractory multiple myeloma.To listen to more podcasts from ASCO, visit asco.org/podcasts.
16 minutes | 2 months ago
News From the 2020 ASH Annual Meeting & Exposition
The 2020 ASH Annual Meeting & Exposition, held in a virtual format this year, begins today. We’re featuring three studies on the podcast this week from the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts.
10 minutes | 2 months ago
Immune-Related Adverse Events and Survival Outcomes in NSCLC
This week, we’re focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment.Coverage of stories discussed this week on ascopost.com:Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With ImmunotherapyTo listen to more podcasts from ASCO, visit asco.org/podcasts.
16 minutes | 3 months ago
Prostate Cancer Highlights From the 2020 ASTRO Annual Meeting
This week, we're focusing on high-impact research in prostate cancer presented during the virtual 2020 ASTRO Annual Meeting. The studies included a focus on GnRH receptor antagonist therapy; imaging-based guidance for radiotherapy intensification; and methods of radiotherapy boosts.To listen to more podcasts from ASCO, visit asco.org/podcasts.
10 minutes | 3 months ago
2020 ASTRO Annual Meeting: High-Impact Research
This week, we’ll be featuring discussions of two late-breaking abstracts presented during the virtual 2020 American Society for Radiation Oncology, or ASTRO, Annual Meeting. The first focuses on the role of imaging to plan treatment with radiotherapy in patients with prostate cancer. The second discusses strategies to manage the pain of spinal metastases. To listen to more podcasts from ASCO, visit asco.org/podcasts.
16 minutes | 3 months ago
Recent FDA Approvals in Leukemia and Lymphoma
This week, we’ll focus on two recent approvals from the U.S. Food and Drug Administration in patients with leukemia and lymphoma, respectively.Coverage of stories discussed this week on ascopost.com:FDA Approves Venetoclax Combination Regimen for Certain Adult Patients With AMLFDA Extends the Approval of Pembrolizumab for Patients With Classical Hodgkin LymphomaTo listen to more podcasts from ASCO, visit asco.org/podcasts.
14 minutes | 4 months ago
ESMO Virtual Congress 2020: Spotlight on Genitourinary Cancers
This week, we’re hearing about three reports on genitourinary cancers presented at ESMO Virtual Congress 2020. We’ll hear directly from the researchers about first-line treatment for metastatic renal cell carcinoma, as well as the long-term results of a doublet therapy for men with advanced hormone-naive prostate cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.
15 minutes | 4 months ago
Veliparib Plus Carboplatin/Paclitaxel in BRCA-Mutated, HER2-Negative Advanced Breast Cancer
We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 TrialNew Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical TrialsFDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLCTo listen to more podcasts from ASCO, visit asco.org/podcasts.
14 minutes | 5 months ago
From the Archive: Insights on Young-Onset Colorectal Cancer
Due to the unexpected passing of actor Chadwick Boseman on August 28, there has been a renewed interest in young-onset colorectal cancer. Mr. Boseman, known for his roles in Black Panther, Marshall, and Get on Up, was only 43 when he died from colon cancer. This week, we’ll go back in The ASCO Post Podcast archives and hear from Kimmie Ng, MD, MPH, who was first on the show about a year ago, offering her insights on the rising rates of colorectal cancer in young adults.
11 minutes | 5 months ago
Highlights From the IASLC Virtual Presidential Symposium
This week on The ASCO Post Podcast, we'll first hear about a study of the monoclonal antibody sintilimab in combination with pemetrexed and platinum to treat advanced nonsquamous non–small cell lung cancer. Then we'll review the results of the CheckMate 743 trial, which suggest a new standard of care in first-line treatment of unresectable malignant pleural mesothelioma.
10 minutes | 5 months ago
Decline in Non–Small Cell Lung Cancer Mortality From 2013 to 2016
We’ll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we’ll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.Coverage of stories discussed this week on ascopost.com:Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in IncidenceAddition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma
16 minutes | 5 months ago
Pathologic Complete Response in the I-SPY2 Trial
This week, we’ll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we’ll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we’ll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved.Coverage of stories discussed this week on ascopost.com:Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast CancerIncreased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease
18 minutes | 5 months ago
New Guidelines on Cervical Cancer Screening
This week, we’ll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we’ll discuss the FDA’s approval of a triplet therapy for advanced melanoma. Lastly, we’ll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.Coverage of stories discussed this week on ascopost.com:American Cancer Society Updates Guideline for Cervical Cancer ScreeningFDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma
11 minutes | 6 months ago
Comparison of Two Combination Treatments in Localized Pancreatic Cancer
This week, we’ll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we’ll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we’ll review the FDA’s recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma.Coverage of stories discussed this week on ascopost.com:First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic CancerAre Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma
17 minutes | 6 months ago
Cabozantinib for Patients With Advanced Bladder Cancer
This week, we’ll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we’ll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we’ll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics. Coverage of stories discussed this week on ascopost.com:Cabozantinib in Platinum-Refractory Metastatic Urothelial CarcinomaCancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted
14 minutes | 6 months ago
Lenvatinib Plus Pembrolizumab for Patients With Advanced Gastric Cancer
This week, we’ll discuss the efficacy of the combination of lenvatinib and pembrolizumab for patients with advanced gastric cancer. We’ll also highlight key points from the recent USPSTF draft recommendation on CT screening for lung cancer. Finally, we’ll review a regulatory approval in metastatic bladder cancer and hear from the principal investigator of the confirmatory trial.Coverage of stories discussed this week on ascopost.com:Lenvatinib Plus Pembrolizumab for Advanced Gastric CancerUSPSTF Issues Draft Recommendation Statement on Screening for Lung CancerFDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma
12 minutes | 6 months ago
Spotlight on Two Breast Cancer Studies From the ASCO20 Virtual Scientific Program
This week, we’ll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB.
17 minutes | 7 months ago
Multiple Myeloma Research From the ASCO20 Virtual Scientific Program
This week, we’ll be hearing from the presenters of three abstracts focused on multiple myeloma presented during the ASCO20 Virtual Scientific Program.
11 minutes | 7 months ago
COVID-19 Research From the ASCO20 Virtual Scientific Program
With this week bringing record highs of COVID-19 infection across the nation, we’re revisiting two presentations from the ASCO20 Virtual Scientific Program on the effect of the virus on patients with cancer.
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2020